愛齊科技 (ALGN) 2017 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Align Technology First Quarter 2017 Earnings Call. (Operator Instructions).

    各位好,歡迎參加 Align Technology 2017 年第一季財報電話會議。(接線員指示)。

  • As a reminder, this conference is being recorded.

    提醒各位,本次會議將被錄音。

  • I would now like to turn the conference over to your host, Ms. Shirley Stacy, VP of Corporate and Investor Communications. Thank you, Ms. Stacy. You may begin.

    現在我想把會議交給今天的主持人——企業與投資人溝通副總裁 Shirley Stacy 女士。謝謝您,Stacy 女士。您可以開始了。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Good afternoon, and thank you, for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.

    各位下午好,感謝各位撥冗參加。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。

  • We issued first quarter 2017 financial results today via Marketwired, which is available in our website at investor.aligntech.com.

    我們今天透過 Marketwired 發布了 2017 年第一季財務結果,您可在我們的網站 investor.aligntech.com 查閱。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern time on May 11. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13658703, followed by pound. International callers should dial (201) 612-7415 with the same conference number.

    今天的電話會議將以音訊網路直播,並在我們網站上存檔約 12 個月。電話重播將於今日約美東時間下午 5:30 提供,並持續至 5 月 11 日美東時間下午 5:30。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the second quarter of 2017. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly and Align expresses -- assumes no obligation to update any forward-looking statements. We've posted historical financial statements including the corresponding reconciliations and our first quarter conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.

    提醒各位,今天簡報人員所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2017 年第二季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 不承擔更新任何前瞻性陳述之義務。我們已在網站「季度結果」專區張貼歷史財務報表(含相應調節表)以及第一季電話會議簡報投影片。如需更詳細資訊,請參閱上述檔案。

  • With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thanks for joining us on our call today. I'll provide some highlights from the quarter and then briefly discuss the performance of our 2 operating segments, Clear Aligners and intra-oral scanners. John will provide more detail on our financial results and discuss our outlook for the second quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.

    謝謝你,Shirley。各位下午好,感謝今天加入我們的電話會議。我將先分享本季的一些重點,接著簡要說明我們兩個營運部門——透明牙套(Clear Aligners)與口內掃描器(intra-oral scanners)的表現。John 會更詳細說明我們的財務結果,並討論第二季展望。之後我會回來總結幾個關鍵重點,並開放提問。

  • 2017 is off to a great start with first quarter revenues, volumes, gross margin and EPS all above expectations. First quarter net revenues were up 30%, year-over-year driven by strong Invisalign case shipments of 27% year-over-year to a record 38.9 thousand doctors this quarter. These reflect growth from both our North American and international regions and higher-than-expected teenage cases across the board, which increased 32% year-over-year. iTero's scanner revenues increased 47% year-over-year, and were down sequentially as expected.

    2017 年開局表現非常亮眼,第一季營收、出貨量、毛利率與每股盈餘(EPS)皆高於預期。第一季淨營收年增 30%,主要受惠於 Invisalign 病例出貨強勁,年增 27%,本季達到創紀錄的 3.89 萬名醫師出貨量。這反映北美與國際市場皆有成長,且青少年病例在各區域均高於預期,年增 32%。iTero 掃描器營收年增 47%,如預期較前一季下滑。

  • For Q1, North American Invisalign case volume was up 8.4% percent sequentially and 20.3% year-over-year driven primarily by North American orthodontists, with GP Dentist showing improving growth trends. Continued strength in North American ortho channel reflects another record quarter for Invisalign utilization, up 12.6 cases per quarter, which includes substantially higher use by teenager patients, a positive indication for market share gains for metal braces.

    第一季北美 Invisalign 病例量較前一季成長 8.4%,年增 20.3%,主要由北美矯正專科醫師帶動;一般牙醫(GP Dentist)的成長趨勢也持續改善。北美矯正通路的持續強勁,反映 Invisalign 使用量再創單季新高,每季增加 12.6 例,其中包含青少年患者使用量大幅提升,這是我們相對於金屬牙套取得市占提升的正面訊號。

  • In Q1, we expand our adult focus media buying to target both men and women with specific segment focus. This new buying target built on the historical strength we have had with adult females, are also reaching adult males in a much more pointed way than ever before. We saw the results of this new media targeting come through in our sales as strength continued with adult females and also significant with adult males choosing it Invisalign treatment.

    在第一季,我們擴大成人族群的媒體投放,針對男性與女性進行更明確的分眾鎖定。這項新的投放策略建立在我們過去在成年女性族群的優勢之上,也以前所未有的更精準方式觸及成年男性。我們在銷售上看到這項新媒體鎖定的成效:成年女性的強勁動能延續,同時也有顯著更多成年男性選擇 Invisalign 治療。

  • During the quarter we launched Invisalign Light in North America, which was at first introduced in EMEA, and includes up to 14 stages aligners. We also beginning piling Invisalign Go in North America in Q1 including with some of our Dental Service Organizations, or DSOs. iGo for short is an aesthetic solution designed to empower general dentists to treat more patients. iGo creates a simplified approach that guides dentists through identifying, planning and treating aesthetic cases.

    本季我們在北美推出 Invisalign Light,該產品最初於 EMEA 地區上市,最多包含 14 個階段的牙套。我們也在第一季開始於北美推廣 Invisalign Go,並涵蓋部分牙科服務組織(Dental Service Organizations,DSO)。簡稱 iGo,是一項美觀解決方案,旨在賦能一般牙醫治療更多患者。iGo 提供一套簡化流程,引導牙醫完成美觀病例的辨識、規劃與治療。

  • On a year-over-year basis, shipment growth of 20.3% was driven by increased adoption of Invisalign by orthodontists and continued expansion of our GP customer base. We continue to make good progress with our DSOs, with Invisalign shipments up nearly 50% year-over-year in Q1, significantly higher than non-DSO practices. DSOs are our leaders in adopting new technology and innovation in dental industry. They were the first to consolidate practices, automate processes and drive greater efficiencies in order to scale their operations. The next phase in the DSO industry shift will be driven by the consumer and their preference for everything digital, which we have branded DSO 3.0 in our new marketing programs and collateral. Consumers today want digital experiences to provide them with more insight to their treatment and options, and what steps to take in order to achieve a healthy lifestyle. By leveraging our technologies, iTero scanning, Invisalign treatment plans, progress-tracking application, time lapse features, our DSOs will be able to collect data on their active patients and tailor dentistry and orthodontics the way their patients want to consume it digitally.

    以年對年來看,出貨成長 20.3% 主要來自矯正專科醫師對 Invisalign 的採用提升,以及我們一般牙醫客戶基礎的持續擴張。我們在 DSO 客戶方面持續取得良好進展,第一季 Invisalign 出貨量年增近 50%,顯著高於非 DSO 診所。DSO 是牙科產業採用新技術與創新的領先者。他們率先整併診所、流程自動化並提升效率,以擴大營運規模。DSO 產業轉型的下一階段將由消費者及其對「全面數位化」的偏好所驅動;我們在新的行銷方案與素材中將其稱為 DSO 3.0。現今消費者希望獲得數位體驗,以更了解其治療與選項,以及為達成健康生活方式所需採取的步驟。透過運用我們的技術——iTero 掃描、Invisalign 治療計畫、進度追蹤應用程式、縮時(time lapse)功能——我們的 DSO 客戶將能蒐集其活躍患者的數據,並以患者希望的數位方式量身打造牙科與矯正服務。

  • Working together with DSOs, we can help accelerate the industry shift to full digital practices much quicker and more effectively than with other companies.

    與 DSO 攜手合作,我們能比其他公司更快速且更有效地協助產業加速轉向全面數位化診所。

  • As part of our newly-formed Americas region, in Q1, we completed the acquisition of our distributor in Brazil, which includes a small team of employees who will be based in our São Paulo offices in Latin America. Brazil is estimated to have approximately 1.4 million new orthodontic case starts each year and employs nearly 20% of the world's dentists. As the world's second largest market for cosmetic interventions, Brazil represents a tremendous growth potential for Align and this acquisition will help us establish our leadership position in Latin America and support our long-term growth strategy.

    作為我們新成立的美洲區域的一部分,我們在第一季完成收購巴西的經銷商;該交易包含一小組員工,將常駐於我們位於拉丁美洲聖保羅的辦公室。據估計,巴西每年約有 140 萬例新的矯正病例開始治療,且擁有接近全球 20% 的牙醫人數。作為全球第二大醫美介入市場,巴西對 Align 具有龐大的成長潛力;此次收購將協助我們在拉丁美洲建立領導地位,並支持我們的長期成長策略。

  • Q1 Invisalign volume for international doctors was up 11.4% sequentially and up 41.3% year-over-year. The better-than-expected sequential increase is driven by growth in both the EMEA and APAC regions.

    第一季國際醫師的 Invisalign 量較前一季成長 11.4%,年增 41.3%。優於預期的季增主要由 EMEA 與 APAC 兩大區域的成長所帶動。

  • In EMEA, Q1 volumes were up 38.8% year-over-year. We had record quarter of growth across nearly all country markets as our TFM model continues gaining traction across the ortho channel, with Spain, the U.K. and Germany leading the way.

    在 EMEA,第一季出貨量年增 38.8%。隨著我們的 TFM 模式在矯正通路持續獲得動能,幾乎所有國家市場都創下成長的紀錄季度,其中以西班牙、英國與德國表現領先。

  • In Q1, we introduced Invisalign Teen with mandibular advancement in certain country markets in EMEA and launched Invisalign Go in the U.K., France and Germany. We also completed the acquisition of our EMEA distributor, which includes opening our first office in the Middle East, which gives us direct access to customers and distribution partners across Russia, Commonwealth of Independent States, the Baltics, Turkey, Monaco, Israel, Cyprus, the Middle East and Africa.

    在第一季,我們在歐洲、中東及非洲(EMEA)部分國家市場推出具下顎前移功能的 Invisalign Teen,並在英國、法國與德國推出 Invisalign Go。我們也完成對 EMEA 經銷商的收購,其中包括在中東設立我們的第一個辦公室,使我們能直接接觸俄羅斯、獨立國協(CIS)、波羅的海國家、土耳其、摩納哥、以色列、賽普勒斯、中東與非洲各地的客戶與通路合作夥伴。

  • In Asia Pacific, Q1 volumes were up 45.2% year-over-year led by China, Japan and Australia and New Zealand. In Q1, we launched Invisalign Teen with mandibular advancement in Australia, New Zealand, Hong Kong and South Asia and more than 800 doctors attending the peer-to-peer launch event. We also held a South Asia forum, with record 200 doctors and participated in New Zealand's Association of Orthodontist forum.

    在亞太地區,第一季出貨量年增 45.2%,主要由中國、日本以及澳洲與紐西蘭帶動。第一季我們在澳洲、紐西蘭、香港與南亞推出具下顎前移功能的 Invisalign Teen,且有超過 800 位醫師參加同儕交流的上市活動。我們也舉辦南亞論壇,創紀錄有 200 位醫師參與,並參加紐西蘭矯正醫師協會論壇。

  • Finally, in South Korea, we transferred all Invisalign practices currently managed by our network partner to a direct coverage model. This gives us 100% direct coverage of the Korean market. It will enable our team to continue developing the market for clear aligners and help accelerate growth and adoption of Invisalign treatment.

    最後,在南韓,我們將目前由網路合作夥伴管理的所有 Invisalign 業務轉為直營覆蓋模式。這使我們對韓國市場達成 100% 直營覆蓋。這將使我們的團隊能持續開發透明矯正器市場,並協助加速 Invisalign 治療的成長與採用。

  • Turning to Teen market. For Q1, 49,000 teenagers started treatment with Invisalign clear aligners, up 11.3% sequentially and 31.6% year-over-year. North America ortho shipment growth was well above the 3-year average both sequentially and year-over-year. International case shipments of teenage patients increased both sequentially and year-over-year as well, with Q1 teen shipments representing about 30% of total teenage cases.

    接著談青少年市場。第一季共有 49,000 名青少年開始使用 Invisalign 透明矯正器治療,較前一季成長 11.3%,較去年同期成長 31.6%。北美矯正通路出貨成長無論較前一季或較去年同期,均明顯高於 3 年平均水準。國際市場的青少年病例出貨也同樣較前一季與去年同期增加,第一季青少年出貨約占青少年總病例的 30%。

  • In Q1, we introduced the first clear aligners solution for Class II correction in certain country markets in Canada, EMEA and APAC. Invisalign Teen with mandibular advancement combines the benefits of the most advanced clear aligner system in the world with features for moving the lower jaw forward while simultaneously, aligning the teeth. This new solution offers a simpler, more efficient and patient-friendly treatment option than functional appliances and without a need for elastics typically used to treat teen Class II patients. It's not available in U.S. yet. It's pending 510(k) approval from regulatory.

    第一季,我們在加拿大、EMEA 與亞太(APAC)部分國家市場推出首個用於第二類咬合(Class II)矯正的透明矯正器解決方案。具下顎前移功能的 Invisalign Teen 結合全球最先進透明矯正系統的優勢,並具備在同時排列牙齒的過程中將下顎向前移動的功能。相較於功能性矯治器,且無需使用通常用於治療青少年第二類咬合患者的橡皮筋,這項新方案提供更簡單、更有效率且更友善患者的治療選擇。目前尚未在美國上市。仍待主管機關核准 510(k)。

  • In Q1, we are excited to launch our new global Made to Move campaign. This is the first time we've had an integrated campaign approach for consumer and professional audience across all regions. The multichannel national consumer campaign will reach patients -- potential patients through TV and digital advertising, social media and PR programs. Launched first in North America, we'll begin to extend our Made to Move campaign in other key country markets beginning in May.

    第一季,我們很高興推出全新的全球「Made to Move」行銷活動。這是我們首次在所有地區針對消費者與專業受眾採取整合式行銷活動策略。此多渠道的全國性消費者行銷活動將透過電視與數位廣告、社群媒體與公關計畫,觸及患者——潛在患者。該活動先在北美推出,我們將自 5 月起開始把「Made to Move」活動延伸至其他關鍵國家市場。

  • While it's still very early, our new campaign is already driving over 40% higher engagement in digital media versus prior media, and followers across Invisalign's social channels are up 13% this quarter. We're also seeing the effectiveness of the new target audience in the media planning. In Q2, we'll launch a significant push to drive consumer demand and conversion with moms and teenagers. We will dial-up our investment in marketing to moms with a the national multitouch campaign under the Made to Move campaign umbrella. And in mid-May, we'll launch our national campaign marketing to teenagers. The national campaign will utilize key social media platforms such as Instagram and SnapChat and YouTube to raise awareness of clear aligners, with custom programming for teens.

    雖然仍在非常早期階段,我們的新活動在數位媒體上的互動度已較先前媒體提高超過 40%,本季 Invisalign 各社群渠道的追蹤者也成長 13%。我們也看到媒體規劃中新目標受眾的成效。第二季,我們將大力推動以媽媽與青少年為對象的消費者需求與轉換。在「Made to Move」活動架構下,我們將透過全國性的多觸點行銷活動,加大對媽媽族群的行銷投資。並於 5 月中旬推出面向青少年的全國性行銷活動。該全國性活動將運用 Instagram、SnapChat 與 YouTube 等主要社群平台,提高對透明矯正器的認知,並為青少年提供客製化內容。

  • In Q1, our Scanner revenues increased 46.9% year-over-year and decreased 33% sequentially as expected. Given we worked through the backlog for iTero elements from the end of last year, these results are more reflective of a typical capital equipment buying cycle which is softer in Q1.

    第一季,我們的掃描儀營收年增 46.9%,並如預期較前一季下滑 33%。由於我們已消化去年底累積的 iTero elements 訂單積壓,這些結果更能反映典型的資本設備採購週期,而第一季通常較為疲弱。

  • This past March, at the International Dental show, IDS we call it in Cologne, we had a greater presence and showcased iTero and Invisalign Go and the benefits of the combination with applications such as Invisalign progress tracking. We also previewed the time lapse application that provides dentists with the ability to compare scans over time to instantly visualize changes in patient's tooth wear, movement and gingival recession. Overall, positive interest as we continue to expand our presence among GPs and EMEA. Use of the iTero Scanners for Invisalign case submission and place of PVS impressions continues to expand and remains a positive catalyst for Invisalign utilization.

    今年 3 月在德國科隆舉辦的國際牙科展(International Dental Show,簡稱 IDS)上,我們擴大參展規模,展示 iTero 與 Invisalign Go,以及兩者結合的優勢與應用,例如 Invisalign 進度追蹤。我們也預覽了縮時(time lapse)應用程式,讓牙醫能隨時間比較掃描結果,即時視覺化患者牙齒磨耗、移動與牙齦萎縮的變化。整體反應正面,我們持續在 EMEA 地區的一般牙醫(GP)族群中擴大能見度。使用 iTero 掃描儀提交 Invisalign 病例並取代 PVS 印模的情況持續擴大,仍是推動 Invisalign 使用量的正向催化因素。

  • For Q1, total Invisalign case submitted with a digital scanner in North America increased to a record 54.4%, up over 10 percentage points from same quarter last year, which reflects an acceleration in case shipments with intra-oral scanners, especially by north American orthodontists.

    第一季,北美使用數位掃描儀提交的 Invisalign 病例占比提升至創紀錄的 54.4%,較去年同期提高超過 10 個百分點,反映口內掃描儀帶動的病例出貨加速,尤其是在北美矯正醫師之間。

  • Q1 was our first full quarter supplying clear aligners to SmileDirectClub and shipments to this new channel were solid. At the beginning of the year, SmileDirectClub launched a consumer advertising campaign that has performed well and is extending the message of treatment with clear aligners versus braces. They've also doubled their network of smile shops, where potential patients can schedule a scan or have 3D impressions and photos taken. Overall we remain excited about the long-term potential for the at-home doctor directed market and working with SmileDirectClub, to bring better smiles to more people.

    第一季是我們向 SmileDirectClub 供應透明矯正器的第一個完整季度,對這個新通路的出貨表現穩健。年初,SmileDirectClub 推出消費者廣告活動,成效良好,並擴大傳遞「使用透明矯正器治療」相較於傳統牙套的訊息。他們也將其 smile shop 網點數量加倍,讓潛在患者可預約掃描或進行 3D 印模與拍照。整體而言,我們仍對居家、由醫師指導的市場長期潛力感到振奮,並期待與 SmileDirectClub 合作,為更多人帶來更美的笑容。

  • With that, I'll turn it over the call to John.

    接下來,我把電話交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe. Let's review our first quarter financial results. Total company revenue for the first quarter was a record $310.3 million, up 5.8% from the prior quarter and up 30% from the corresponding quarter a year ago. Clear aligner revenue of $282.4 million was up 12.3%, sequentially driven primarily by better-than-expected Invisalign shipments and higher Invisalign ASPs. Year-over-year Clear Aligner revenue growth of 28.5% reflected strong Invisalign shipment growth across all customer channels and geographies, partially offset by foreign exchange rates.

    謝謝,Joe。我們來回顧第一季的財務結果。第一季公司總營收創新高,達 3.103 億美元,較前一季成長 5.8%,較去年同期成長 30%。透明矯正器營收為 2.824 億美元,較前一季成長 12.3%,主要受惠於 Invisalign 出貨優於預期以及 Invisalign 平均銷售單價(ASP)提高。透明矯正器營收年增 28.5%,反映各客戶通路與各地區的 Invisalign 出貨強勁成長,但部分被匯率因素抵銷。

  • Q1 Invisalign ASPs were up sequentially approximately $40 from Q4 to $1,270, reflecting lower promotional activity. On a year-over-year basis, Q1 Invisalign ASPs were up approximately $15 primarily due to price increases, partially offset by increased promotional discounts, product shift to low-stage products and foreign-exchange.

    第一季 Invisalign 的 ASP 較第四季按季上升約 40 美元至 1,270 美元,反映促銷活動減少。以年對年來看,第一季 Invisalign 的 ASP 約增加 15 美元,主要因價格調漲,但部分被促銷折扣增加、產品組合轉向低階段產品以及匯率因素所抵銷。

  • For the first quarter, total Invisalign shipments of 208.1 thousand cases were up 9.5% sequentially, driven primarily by North American orthodontists and international doctors. Year-over-year Invisalign case growth volume was 27.1%, driven by growth across all regions as well as expansion of our customer base, predominantly from the Asia Pacific region.

    第一季 Invisalign 總出貨量為 20.81 萬例,較前一季成長 9.5%,主要由北美矯正醫師與國際醫師帶動。Invisalign 病例量年增 27.1%,由各地區成長以及客戶基礎擴張所驅動,其中以亞太地區貢獻為主。

  • For North American orthodontists, Q1 Invisalign case volume was up 13.6% sequentially, and up 27.5% year-over-year. For North American GP dentists, Invisalign case volume was up 2% sequentially and up 11.4% year-over-year.

    就北美矯正醫師而言,第一季 Invisalign 病例量較前一季成長 13.6%,較去年同期成長 27.5%。就北美一般牙醫(GP)而言,Invisalign 病例量較前一季成長 2%,較去年同期成長 11.4%。

  • For international doctors, Invisalign case volume was up 11.4% sequentially and 41.3% year-over-year. Worldwide Invisalign utilization in Q1 was a record 5.4 cases per doctor, up from 4.9 in Q1 last year. North America ortho utilization was a record 12.6, up from 10.4 the prior year. North America GP utilization was 3.1, up slightly from 3.0 the prior year. And international utilization was 5.0, up from 4.7 in Q1 last year, reflecting continued expansion of our customer base in Asia Pacific.

    就國際醫師而言,Invisalign 病例量較前一季成長 11.4%,較去年同期成長 41.3%。第一季全球 Invisalign 使用率創新高,達到每位醫師 5.4 例,高於去年第一季的 4.9 例。北美矯正科使用率創新高,達到 12.6,高於前一年的 10.4。北美一般牙科(GP)使用率為 3.1,較前一年的 3.0 略增。國際使用率為 5.0,高於去年第一季的 4.7,反映我們在亞太地區客戶基礎持續擴張。

  • In Q1, we added 3,260 new Invisalign doctors worldwide, of which 980 were new North American doctors and 2,280 of which were new international doctors. This compared to 3,700 in Q4 and 2,480 total doctors trained in the same quarter last year.

    第一季我們在全球新增 3,260 位 Invisalign 醫師,其中 980 位為新增北美醫師,2,280 位為新增國際醫師。相較之下,第四季新增 3,700 位,而去年同期受訓醫師總數為 2,480 位。

  • Our Scanner and services revenue for the first quarter was $27.9 million, down 33% sequentially and up 46.9% year-over-year.

    第一季掃描儀與服務營收為 2,790 萬美元,較前一季下降 33%,較去年同期成長 46.9%。

  • Moving on to gross margin. First quarter overall gross margin was 75.9%, up 0.8 points sequentially and 0.2 points year-over-year. Clear Aligner gross margin for the first quarter was 77.9%, up 0.4 points sequentially primarily due to leveraging our manufacturing costs over higher volumes, higher Invisalign ASPs and partially offset by increased aligners per case. Clear Aligner gross margins were down 0.4 points year-over-year, primarily due to increased aligners per case as we continue to treat more complex cases, partially offset by manufacturing efficiencies.

    接著談毛利率。第一季整體毛利率為 75.9%,較前一季提高 0.8 個百分點,較去年同期提高 0.2 個百分點。第一季透明牙套(Clear Aligner)毛利率為 77.9%,較前一季提高 0.4 個百分點,主要因為在較高出貨量下攤提製造成本、Invisalign 平均售價(ASP)提高,但部分被每案牙套數增加所抵銷。透明牙套毛利率較去年同期下降 0.4 個百分點,主要因為隨著我們持續治療更複雜的病例,每案牙套數增加;部分被製造效率提升所抵銷。

  • Scanner gross margin for the first quarter was 56.1%, down 4.9 points sequentially primarily due to a slight increase in excess and obsolescence reserves and higher freight cost.

    第一季掃描儀毛利率為 56.1%,較前一季下降 4.9 個百分點,主要因為超額與報廢(E&O)備抵略為增加,以及運費成本較高。

  • Scanner segment gross margin was up 11.1 points year-over-year, primarily a result of higher ASPs and lower manufacturing and servicing costs of our iTero Element Scanner relative to our previous scanner.

    掃描儀部門毛利率較去年同期提高 11.1 個百分點,主要是因為平均售價(ASP)較高,以及相較於我們先前的掃描儀,iTero Element 掃描儀的製造與維修成本較低。

  • Q1 operating expenses were $174 million, up sequentially by $22.1 million or 14.5% primarily related to increased employee headcount, commissions associated with higher volumes and marketing spend as a result of our investments in geographic expansion, our new advertising campaign and the commercialization of new products.

    第一季營業費用為 1.74 億美元,較前一季增加 2,210 萬美元或 14.5%,主要與員工人數增加、因出貨量提高而增加的佣金,以及因我們在地理擴張、新廣告活動與新產品商業化方面的投資而增加的行銷支出有關。

  • On a year-over-year basis, Q1 operating expenses were up 36.7%, reflecting the aforementioned investments.

    以年對年來看,第一季營業費用增加 36.7%,反映前述投資。

  • Our first quarter operating margin was 19.9%, down 3.4 points sequentially and 2.4 points year-over-year. The sequential decrease in operating margin relates primarily due to increased headcount and marketing expenses as we continue to grow our business. On a year-over-year basis, decreased operating margin primarily reflects the higher operating expenses as we invest in headcount, geographic expansion and new products in order to increase the adoption and accelerate the growth of our business.

    第一季營業利益率為 19.9%,較前一季下降 3.4 個百分點,較去年同期下降 2.4 個百分點。營業利益率的季對季下降主要與人力增加及行銷費用增加有關,因為我們持續擴大業務。以年對年來看,營業利益率下降主要反映營業費用較高,因我們投資於人力、地理擴張與新產品,以提高採用率並加速業務成長。

  • With regards to the first quarter tax provision. Our tax rate was minus 11.4%, which includes $21.3 million in excess tax benefits and is down by approximately 31.2 points compared to Q4 of '16.

    關於第一季所得稅提列。我們的稅率為負 11.4%,其中包含 2,130 萬美元的超額稅務利益,較 2016 年第四季約下降 31.2 個百分點。

  • In our first quarter of 2017, we adopted accounting standards update entitled improvements to employee share-based payment accounting. Under this new standard, excess tax benefits and deficiencies associated with employee share-based payments are no longer recognized as additional paid-in capital on the balance sheet but instead, recognized directly to income tax expense or benefit in the income statement for the reporting period in which they occur.

    在 2017 年第一季,我們採用一項會計準則更新,題為「員工股份基礎給付會計之改進」。依據此新準則,與員工股份基礎給付相關的超額稅務利益與不足,不再於資產負債表中認列為額外實收資本,而是於其發生之報導期間,直接在損益表中認列為所得稅費用或利益。

  • We also supply aligners to SmileDirectClub and therefore, revenue and cost for this activity are included in our operating profit and reported results. Although, they were immaterial to the company this quarter. Additionally, we also report our share of SmileDirectClub's losses below operating margin and our tax provision and is entitled equity and losses of investee net of tax. This Q1 loss net of tax was approximately $1.1 million or $0.01 per diluted share.

    我們亦向 SmileDirectClub 供應牙套,因此此項活動的收入與成本均納入我們的營業利益與已報告結果中。不過,本季對公司而言影響不重大。此外,我們也在營業利益率與所得稅提列之下方,報告我們分攤的 SmileDirectClub 虧損,項目名稱為「被投資公司權益損益(扣稅後)」。第一季扣稅後虧損約為 110 萬美元,或每股稀釋後虧損 0.01 美元。

  • First quarter diluted earnings per share was $0.85 compared to $0.59 reported in Q4, and $0.50 reported in the same quarter last year. First quarter earnings per share included the benefit of $21.3 million or $0.26 per share from excess tax benefit on stock-based compensation in accordance with the new standard.

    第一季稀釋後每股盈餘為 0.85 美元,相較第四季為 0.59 美元,去年同期為 0.50 美元。依據新準則,第一季每股盈餘包含因股票基礎薪酬之超額稅務利益帶來的 2,130 萬美元或每股 0.26 美元的利益。

  • Moving on to the balance sheet. As of the first quarter, cash, cash equivalents and marketable securities including both short and long-term investments were $644.2 million. This compared to $700 million at the end of 2016, a decrease of approximately $56 million primarily related to the purchase of our new headquarters building.

    接著談資產負債表。截至第一季末,現金、約當現金與有價證券(包含短期與長期投資)為 6.442 億美元。相較於 2016 年底的 7.00 億美元,約減少 5,600 萬美元,主要與購置新總部大樓有關。

  • Of the $644.2 million of cash, cash equivalents and marketable securities, $222.7 million was held by the U.S. and $421.5 million was held by our international entities.

    在 6.442 億美元的現金、約當現金與有價證券中,2.227 億美元由美國持有,4.215 億美元由我們的國際實體持有。

  • Q1 accounts receivable balance was $267.1 million, up approximately 8% sequentially. Our overall DSO was 77 days, up 1 day sequentially and up 10 days year-over-year. The increase is a result of our ERP and other related systems implementation last July, which have impacted the timing of our customer collections. We anticipate that our DSOs will remain above our historical average for several more quarters as we work through these changes.

    第一季應收帳款餘額為 2.671 億美元,較前一季約增加 8%。整體應收帳款週轉天數(DSO)為 77 天,較前一季增加 1 天,較去年同期增加 10 天。此增加係因我們於去年 7 月導入 ERP 與其他相關系統,影響了客戶收款時點。我們預期在消化這些變更的過程中,DSO 將在未來數季仍高於歷史平均。

  • Cash flow from operations for the first quarter was $47.6 million. During the quarter, we used $36.5 million to pay employee taxes for the net settlement of vesting employee stock awards that otherwise would have been issued.

    第一季營運活動現金流量為 4,760 萬美元。本季我們使用 3,650 萬美元支付員工稅款,係因員工股票獎酬歸屬時採淨額交割(原本將發行的股份因此未發行)。

  • Capital expenditures for the first quarter were $59.6 million, primarily related to the purchase of our new facilities in San Jose, California, as well as equipment purchases for additional manufacturing capacity and building improvement.

    第一季資本支出為 5,960 萬美元,主要與購置位於加州聖荷西的新設施,以及為增加製造產能的設備採購與建物改善有關。

  • During the first quarter, we repurchased approximately 40,000 shares of stock for $3.8 million, which completes the April 2014 repurchase plan. We have $300 million available for repurchase under the 2016 repurchase program that was announced on April 28, 2016.

    第一季期間,我們以 380 萬美元回購約 40,000 股股票,完成 2014 年 4 月的回購計畫。在 2016 年回購計畫(於 2016 年 4 月 28 日宣布)下,我們仍有 3.00 億美元可用於回購。

  • With that, let's turn to our business outlook and the factors that inform our view. Starting with the demand outlook. For our international markets, expect seasonally higher period for APAC and EMEA. For North America, seasonally up for orthos and GP dentists. For our Scanner business, Q2 equipment purchases are seasonally higher. With this as a backdrop, we expect the second quarter to shape up as follows: Invisalign case volume is anticipated to be in the range of 221,000 to 224,000 cases, up approximately 25% to 27% over the same period a year ago, reflecting continued strong demand across all channels and regions; we expect Q2 net revenues to be in the range of $340 million to $345 million, an increase of 26% to 28% year-over-year; we expect Q2 gross margins to be in the range of 74% to 75%, reflecting a higher mix of iTero business and aligned manufacturing expansion in Asia Pacific; we expect Q2 operating expenses to be in the range of $180 million to $184 million, up quarter-over-quarter primarily due to increased headcount, increased marketing expenses related to our new Invisalign brand and teen campaigns; Q2 operating margin should be in the range of 21% to 22%; our effective tax rate including a windfall benefit of $2 million to $3 million should be approximately 21%; we estimate that Q2 impact of the SmileDirectClub transaction to not significantly impact EPS; and diluted shares outstanding should be approximately 81.6 million, exclusive of any share repurchases.

    接下來,讓我們轉到我們的業務展望,以及支撐我們觀點的因素。先從需求展望談起。就我們的國際市場而言,預期亞太(APAC)與歐洲、中東及非洲(EMEA)將進入季節性較旺的期間。就北美而言,矯正科醫師與一般牙醫(GP)將呈現季節性走升。就我們的掃描器業務而言,第二季設備採購具有季節性較高的特徵。在此背景下,我們預期第二季表現如下:Invisalign 病例量預計介於 221,000 至 224,000 例,較去年同期約成長 25% 至 27%,反映各通路與各區域需求持續強勁;我們預期第二季淨營收介於 3.40 億至 3.45 億美元,年增 26% 至 28%;我們預期第二季毛利率介於 74% 至 75%,反映 iTero 業務占比提高,以及亞太地區配合的製造產能擴張;我們預期第二季營業費用介於 1.80 億至 1.84 億美元,較前一季增加主要因人力增加,以及與全新 Invisalign 品牌與青少年行銷活動相關的行銷費用增加;第二季營業利益率應介於 21% 至 22%;包含 200 萬至 300 萬美元一次性稅務利益(windfall benefit)在內的有效稅率約為 21%;我們估計 SmileDirectClub 交易對第二季 EPS 的影響不重大;稀釋後流通在外股數約為 8,160 萬股,不含任何庫藏股回購。

  • Taken together, we expect our Q2 diluted earnings per share to be in the range of $0.71 to $0.74, which includes approximately $0.03 of excess tax benefit.

    綜合以上,我們預期第二季稀釋後每股盈餘介於 0.71 至 0.74 美元,其中包含約 0.03 美元的超額稅務利益。

  • In addition, as we continue to operational -- continue our operational expansion efforts, we expect CapEx for Q2 to be approximately $30 million to $35 million.

    此外,隨著我們持續推進營運擴張—持續推進我們的營運擴張工作,我們預期第二季資本支出(CapEx)約為 3,000 萬至 3,500 萬美元。

  • Now, let me turn to our view of 2017. Given the stronger-than-expected results we've seen to-date, we now anticipate 2017 total revenue to be at the high-end of our long-term operating model range of 15% to 25%.

    現在,讓我談談我們對 2017 年的看法。鑑於迄今為止我們看到的業績優於預期,我們目前預期 2017 年總營收將落在我們長期營運模型 15% 至 25% 區間的高端。

  • We also expect Invisalign revenue and volume growth to be at the high-end of that model. Notwithstanding continued investments in our strategic growth drivers, we remain comfortable with the operating margin for the full year to be flat to slightly up from 2016 operating margin of 23%.

    我們也預期 Invisalign 的營收與病例量成長將位於該模型區間的高端。儘管我們持續投資於策略性成長驅動因素,我們仍有信心全年營業利益率可與 2016 年 23% 的營業利益率持平至小幅上升。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    接下來,我把時間交回 Joe 做最後結語。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John. In closing, I'm pleased with our continued progress and execution of our strategic growth drivers. The dental industry remains healthy and our customers continue to report solid patient traffic in their offices. I just returned from the AAO meeting in San Diego this week and was excited to see the level of activity in our booth and the interest level in our products, especially for teenagers as we kick off the summer teen season with our new teen-focused campaign. We had 2,000 doctors and their staff visit our booth and 300 attendees participated in our iTero, our record scanning challenge, wherein an iTero scan was completed in under 1 minute for the first time in competition.

    謝謝,John。最後,我對我們在策略性成長驅動因素上的持續進展與執行力感到滿意。牙科產業仍然健康,我們的客戶也持續回報其診所病患來訪量穩健。我本週剛從聖地牙哥的 AAO 會議返程,很高興看到我們攤位的活動熱度與對我們產品的興趣程度,尤其是針對青少年;我們以全新的青少年主題行銷活動,正式啟動暑期青少年旺季。共有 2,000 位醫師及其員工造訪我們的攤位,並有 300 位與會者參加我們的 iTero「破紀錄掃描挑戰」,在競賽中首次將 iTero 掃描時間縮短至 1 分鐘內完成。

  • We will be in Dubai in May, hosting our EMEA summit with over 400 customers attending the 2-day peer-to-peer event.

    我們將於 5 月前往杜拜,主辦 EMEA 高峰會,將有超過 400 位客戶參加這場為期兩天的同儕交流活動。

  • We've got a lot going on in Q2 and I look forward to sharing more with you at the upcoming financial conference and meetings.

    第二季我們有很多事情在進行,我也期待在即將到來的財務研討會與會議上與各位分享更多資訊。

  • I'll now open the call to questions. Operator?

    現在我開放提問。接線員?

  • Operator

    Operator

  • (Operator Instructions) Our first person comes from the line of Robert Jones of Goldman Sachs.

    (接線員指示) 第一位提問者是來自高盛(Goldman Sachs)的 Robert Jones。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • I guess, just looking at the significant step up in case growth for ortho in North America. And in particular, Joe, you highlighted, a couple times on the call that the impressive teen growth, which accelerated materially. I'm curious, you had a few initiatives at play in the quarter. Anything you can share on how much of the teen growth, specifically within ortho North America, was because of things like the teen challenge versus some of the more tactical changes you had within the sales force? And I'm thinking about doc locator and things of that nature.

    我想先談北美矯正通路病例成長顯著加速的情況。特別是 Joe,你在電話會議中提到好幾次,青少年成長非常亮眼,而且明顯加速。我很好奇,本季你們同時推動了幾項措施。你能否分享一下,在北美矯正通路中,青少年成長有多少是來自像「teen challenge」這類活動,相較於你們在銷售團隊內部做的一些較戰術性的調整?我想到的是醫師搜尋/導引(doc locator)之類的工具與措施。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Bob, it's a good question and we've asked ourselves this question during the quarter too, as unfortunately, we don't do single, variable equations around here. We have a number of things we've done with teens. And again, we'll make it more complicated as we get into more intense advertising in the second quarter. But you mentioned teen challenge. We think it certainly, had an impact in this sense, I think, some of the changes we've made on doc locator and the sense of specificity of the patient directive into accounts, was is part of that also. Also, our next level partnership parts with customers which basically takes customers to another level depending upon the share of business that we receive or the accelerated growth level that they can provide to us. Remember, when you go back about 75% of the normal orthodontic cases in the United States are teen-based. So if you want to do more Invisalign, it's going to be hard to just dip into adults, if you really want to increase in that sense and you have to look at your teen business too. So I'd say those 3 major variables is what really we -- what drove, from a North American standpoint, the teen growth in the first quarter.

    Bob,這是個好問題,我們在本季也一直在問自己同樣的問題;但不巧的是,我們這裡沒辦法用單一變數方程式來拆解。我們針對青少年做了很多事情。而且,隨著第二季更密集的廣告投放,情況會變得更複雜。不過你提到 teen challenge,我們認為它確實帶來了影響;同時,我認為我們在 doc locator 上做的調整,以及更精準地把病患導流到特定診所帳戶的做法,也是一部分原因。此外,我們與客戶的「下一層級合作夥伴」計畫,基本上會依據我們取得的業務占比,或客戶能提供給我們的加速成長幅度,將客戶提升到另一個層級。請記得,回頭看美國一般矯正病例中約 75% 是青少年。因此,如果你想做更多 Invisalign,只靠成人市場很難大幅增加;若要在這個意義上提升,你也必須看青少年業務。所以我會說,從北美角度來看,第一季青少年成長主要就是由這三個關鍵變數所驅動。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • Got it. So no one stood out more than other?

    了解。所以沒有哪一項特別比其他更突出?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No, couldn't separate it.

    對,無法拆分出來。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • And then I guess, just my follow-up on the early recently launched products that you mentioned, like Invisalign Lite, Invisalign Go, mandibular advancement. Given those are still relatively new within the case numbers that you're sharing, how should we think about these products helping accelerate or play into case growth as we move throughout the year?

    那我接著追問一下你提到的近期剛推出的產品,例如 Invisalign Lite、Invisalign Go、下顎前移(mandibular advancement)。考量這些產品在你們分享的病例數中仍相對較新,我們應該如何看待這些產品在今年接下來的時間裡,對病例成長的加速或貢獻?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I can't give you -- John can help you on the dimensions of it. But I'd say, when you talk about the mandibular advancement, which is completely different animal than the -- like the 15 stage we have for Lite, the Lite product fits really well when you think about E5, E10 and now E15. Customers can understand it, they can integrate it. We saw really rapid uptake with that product line. When you come up with new products in this business like mandibular advancement, the infusion rate into the marketplace is slow. You really -- you have dentists and orthodontists who want to try the product, they want to see how it works. They're just cautious on the front-end until they gain confidence with it. So I mean, mandibular advancement, remember we don't have a 510(k) in United States yet. We have to -- that will occur later this year, we hope so. But we will launch it the rest of the way, around the world. And that product is truly a breakthrough. We'll have to work hard from a peer-to-peer standpoint to help to promote it, whatever. But it gives us more credibility again, in that teen market than we had before. But I wouldn't look at significant -- I wouldn't look at material numbers from mandibular advancement in 2017, in any way. It will be as how fast we can infuse that product in the marketplace.

    我沒辦法給你—John 可以在規模面向上補充。但我會說,談到下顎前移(mandibular advancement),它完全是不同的產品類型,不像 Lite 的 15 個階段(stage)。Lite 產品線在你想到 E5、E10、以及現在的 E15 時非常契合。客戶能理解,也能把它整合進既有流程。我們看到該產品線採用速度非常快。但當你在這個產業推出像下顎前移這種新產品時,導入市場的滲透速度會比較慢。你會看到牙醫與矯正科醫師想先試用產品、想先看看效果如何。在前期他們會比較謹慎,直到建立信心為止。另外,下顎前移請記得,我們在美國目前還沒有取得 510(k)。我們必須—我們希望能在今年稍晚取得。但我們會在全球其他地區全面推出。而那項產品確實是突破性的。我們必須從同儕對同儕(peer-to-peer)的角度努力推廣它等等。但它也讓我們在青少年市場的可信度比以前更高。不過我不會把 2017 年下顎前移的貢獻看得很大—我不會預期它在 2017 年帶來顯著、或具重大性(material)的數字。它的表現將取決於我們能多快把這個產品導入市場。

  • Operator

    Operator

  • Our next question comes from the line of Steve Beuchaw of Morgan Stanley.

    我們的下一個問題來自摩根士丹利(Morgan Stanley)的 Steve Beuchaw。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • Yes, so I've never been someone who congratulated a company on a great quarter, and I'm not going to do that here but you know it was a great quarter. But I'm going to be the first to congratulate you on joining the $10 billion market cap club here in the aftermarket.

    是的,所以我從來不是那種會因為一家公司某一季表現很好就恭喜對方的人,我在這裡也不打算這麼做,但你知道,這確實是一個很棒的季度。不過我要成為第一個恭喜你們在盤後加入 100 億美元市值俱樂部的人。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Steve. That's great.

    謝謝你,Steve。太好了。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • So I -- hopefully, I was first in the queue on that one. Just a couple for me. And I completely agree, of course, with Bob that when you look at the quarter, you have to take a step back and say, wow, this is the fastest growth I've seen in -- certainly, in my model, it's fairly remarkable to step up. Teen really jumps out. I wonder if you could sort of hypothesize for me about how important the one-week aligner changeout was, specifically? I know you called it out briefly but could you just dive a little bit deeper there? And could you give us a sense for -- specifically, in the U.S., because a lot of investors really like to focus on this point. Just how much faster teen growth was relative to the '16 trend? You mentioned it was faster but could you give us any more granularity there?

    所以我——希望我在這件事上是排隊第一個。我這邊只有幾個問題。而且我當然完全同意 Bob 的看法:當你看這一季時,你得退一步說,哇,這是我見過最快的成長——至少在我的模型裡,這樣的躍升相當驚人。青少年(teen)真的非常突出。我想請你們幫我推測一下:特別是「每週更換一次隱形牙套」這件事到底有多重要?我知道你們有簡短提到,但能否再深入一點?另外能否給我們一些感覺——特別是在美國,因為很多投資人很喜歡聚焦在這點上。青少年成長相較於 2016 年的趨勢到底快了多少?你們提到更快,但能否提供更細的資訊?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I'll take the first one. I'll give John the second one on this one, Steve. On growth trial on one-week wear piece, again, it's hard to pull that signal out from the volume noise, I'd call it but what we see is, we're seeing a rapid uptake by our orthodontists and GPs on moving to 7-day kind of aligner wear. We're also getting good feedback in a sense that helps them in a close cycle with patients to know that those particular episodes are going to last some sometimes -- half the time of what another one was. So it becomes another item in that discussion that's really helpful. So it's certainly helping us again, but I can't quantify to the extent of what it is. As far as the U.S. and the faster piece that you mentioned before, John will do it, Steve.

    第一個我來回答。第二個我請 John 來回答,Steve。關於每週配戴(one-week wear)這一塊對成長的帶動,再次強調,很難把這個訊號從量的雜訊中抽離出來,但我們看到的是:我們的矯正專科醫師與一般牙醫(GPs)正在快速採用 7 天一換的牙套配戴方式。我們也收到不錯的回饋,因為這有助於他們與病患形成更緊密的療程節奏,讓病患知道某些療程階段的時間有時會——縮短到原本另一種方式的一半。因此,這成為討論中另一個非常有幫助的要素。所以它確實在幫助我們,但我無法量化其影響程度。至於你先前提到的美國以及更快的那一塊,Steve,就由 John 來回答。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Steve, was your question specifically, on teen growth in the U.S.? Or with ...

    Steve,你的問題是特別針對美國的青少年成長嗎?還是……

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • Exactly.

    沒錯。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, I mean, teen growth -- we have an overall growth model built in. This is definitely faster than we had built in initially and that's what led to some of our upside that we saw in the first quarter. So teen was definitely stronger than and we would've modeled out so far this year.

    是的,我是說,青少年成長——我們有一個整體的成長模型。這確實比我們一開始納入模型的速度更快,而這也帶來了我們在第一季看到的一些上行表現。所以青少年確實比我們今年迄今所建模的情況更強。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Yes, and I think -- just adding to what John said, Steve, the comment that we made about teen -- North American ortho teen growth being faster than the last 3-year average. That gives you a couple of things to look at.

    是的,我想——補充 John 的話,Steve,我們提到的關於青少年(teen)的評論是:北美矯正(ortho)青少年成長速度快於過去 3 年的平均值。這會給你幾個可以參考的面向。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • Got it. As I was at the Align booth at IDS, I thought the message that I'm getting here from the teen is very clearly that this just almost isn't an orthodontics company anymore. This is a company that wants to and has now taken a big step towards becoming a bigger part of the doc office, is sort of consumer brand. And I understand that your ambitions are to become a true consumer power, maybe the Nike of oral health care. Joe, it would be really helpful now that you've seen some of the progress with these initiatives. And some of the progress with SDC, for that matter, if you could just sort of refresh us on your thinking on the path there and how this plays into your thinking about the 15% to 25% range with the business really sitting at the high-end?

    了解。我在 IDS 的 Align 攤位時,我覺得我從青少年這塊得到的訊息非常清楚:這幾乎不再只是一家矯正公司了。這是一家想要、而且現在已經大步邁向成為診所端更重要一部分、並且有點像消費者品牌的公司。我也理解你們的企圖心是成為真正的消費者力量,也許是口腔健康照護領域的 Nike。Joe,現在你已經看到這些計畫的一些進展,以及就 SDC 而言的一些進展,如果你能幫我們更新一下你對這條路徑的想法,以及這如何影響你對 15% 到 25% 區間的看法(而目前業務實際上處在區間高端),那會非常有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Steve, first of all, you saw our presence at IDS. We had a strong presence down at the AAO in San Diego. But when I hear your comments like that, one thing I want to make sure is that we're not looking at ourselves as a general dentistry company. We do clear aligner systems and we do scanners and we don't have the kind of penetration in the marketplace we think we should have, here and anywhere in the world. And so we'll stay focused on those items. So don't -- I don't want anyone to think that we're trying to broaden our wins to become a more of a general dentistry company. It's not what is kind of in the cards. I think, what you -- when you -- Steve, you look at the Google searches that have really rocketed for Clear Aligners over the last quarter or so, some heavy investing by SDC and also, having an investing by us, it's generating a lot of interest from a consumer standpoint in the marketplace. More and more, we know we have a strong consumer brand and we'll reach out to consumers to try to drive that. But again, I want to emphasize, we are doctor-directed kind of a product line and we work through our docs to get these things done and we do want to establish a strong brand identity with consumers as they turn into patients but at the same time, we don't have a direct-to-consumer kind of model that we're pushing at the moment. We -- that's exercised through SDC and are supplied for those kinds of things. I hope -- does that help, Steve? Does that make sense to you?

    Steve,首先,你看到了我們在 IDS 的曝光。我們在聖地牙哥的 AAO 也有很強的存在感。但當我聽到你這樣的評論時,我想先確保一件事:我們並不把自己視為一家一般牙科公司。我們做的是透明矯正系統(clear aligner systems)以及掃描器(scanners),而我們在市場上的滲透率——無論是在這裡或世界任何地方——都還沒有達到我們認為應該有的程度。因此我們會持續聚焦在這些項目上。所以——我不希望任何人以為我們想要擴大戰線、變成更像一般牙科公司。這並不是我們規劃中的方向。我想,Steve,當你看到過去一季左右「透明牙套(Clear Aligners)」的 Google 搜尋量大幅飆升,這部分來自 SDC 的大量投資,同時我們也有投入,從消費者角度來看,這正在市場上引發很大的興趣。我們越來越清楚我們擁有強勢的消費者品牌,我們也會觸及消費者來嘗試推動這件事。但我還是要強調:我們是以醫師主導(doctor-directed)的產品線,我們透過醫師來完成這些治療;我們確實希望在消費者端建立強而有力的品牌識別,當他們轉化為病患時能夠認同我們,但同時,我們目前並沒有在推動直接面向消費者(direct-to-consumer)的模式。這部分是透過 SDC 來執行,而我們則供應這類需求。我希望——這有幫助嗎,Steve?你覺得這樣說清楚嗎?

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • Right, it's loud and clear.

    對,很清楚。

  • Operator

    Operator

  • Our next question comes from the line of Richard Newitter of Leerink Partners.

    我們的下一個問題來自 Leerink Partners 的 Richard Newitter。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • And I will congratulate on the quarter -- on a great quarter because it really was. The first question I just had on SmileDirectClub. In the past, we've heard some discussion from orthodontists who are a little nervous with what this might mean for their practice. I'm just wondering, can you update us on where the conversations have been at their respective conferences you've attended so far? Clearly, some of the initiatives you have in place from an advertising standpoint, they must be drawing in new patients. So I'm assuming orthodontists are getting comfortable that it's not going to cannibalize their business. But any update there? And then, I have a follow-up.

    我會恭喜你們這一季——恭喜一個很棒的季度,因為確實如此。我第一個問題是關於 SmileDirectClub。過去我們聽到一些矯正專科醫師的討論,他們對這可能對其診所業務意味著什麼有點緊張。我想請問,你們能否更新一下:到目前為止,在你們參加的各個相關會議上,與他們的對話進展如何?很明顯,你們在廣告方面的一些措施應該正在帶來新病患。所以我推測矯正醫師正在逐漸放心,認為這不會侵蝕他們的業務。但這方面有任何更新嗎?然後我還有一個追問。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, Rich, you know I'd say, we announced July, last year the SDC relationship that we have. There is a lot of constant turmoil in the industry in a sense of what we did and why we did it. We continue to explain to our customer base and sense of the logic behind that. Their business continues to expand and the market continues to expand. So I think there -- I can't tell you that this will ever go away. There's -- still I would quantify it as a large amount of anxiety in the marketplace. I don't think that will change. What I do find though, Rich, is that customers that do a significant amount in Invisalign and then have a good relationship with Align, tend to understand this more or accept it more. Ones that haven't and ones that stay more in the metals and brackets, I think have been more boisterous or more concerned in some of our -- now that's empirical. I can't give you any statistics specifically on our customer base on that but it's what I feel. But I -- overall, I think as time goes on and the orthodontic market continues to expand as well as the consumer market continues to expand, and the -- I think it generates, as we said before, a huge amount of business goes to the GPs and the orthos that use Invisalign and we'll continue to recycle patients that don't fit the protocols that SDC has into the current consumer -- customer base that we have. So I'd just say, we have to keep working it, Rich. If we're not out of the woods in the sense of the discomfort of our customers. But we'll keep driving the same message, we'll keep bringing business into those accounts to help those accounts grow and hopefully, they'll reach a higher comfort level over time.

    是的,Rich,你知道我會說,我們在去年7月宣布了我們與SDC的合作關係。就我們做了什麼以及為什麼這麼做而言,業界一直存在相當多的持續動盪。我們也持續向我們的客戶群說明並闡述其背後的邏輯。他們的業務持續擴張,市場也持續擴張。所以我想——我無法告訴你這件事是否會永遠消失。市場上仍然——我會量化為相當程度的焦慮。我不認為那會改變。不過我發現的是,Rich,那些在Invisalign上做了相當大量業務、而且與Align維持良好關係的客戶,往往更能理解或更能接受這件事。而那些沒有、以及仍較多停留在金屬矯正器與托槽的客戶,我認為在我們的一些——現在這是經驗觀察——他們更為高調或更為擔憂。我無法就我們客戶群提供任何具體統計數據,但這是我的感受。但我——整體而言,我認為隨著時間推進,正畸市場持續擴張、消費者市場也持續擴張,而且——我認為這會帶來,如我們先前所說,大量業務會流向使用Invisalign的全科牙醫(GP)與正畸醫師(ortho),而我們也會持續把不符合SDC方案規範的患者回流到我們現有的消費者——客戶群中。所以我只能說,我們必須持續推進這件事,Rich。就客戶不適感而言,我們還沒有完全走出困境。但我們會持續傳達同樣的訊息,持續把業務帶進那些帳戶以協助其成長,並希望他們隨時間推移能達到更高的舒適度。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • Okay, that's helpful. And then just one follow-up. On the distributor acquisitions you're doing internationally, wondering if you could just quantify the contribution that you saw in the quarter and what we should think going forward? And also, are there are additional ones we should expect in future quarters, aside from the ones you executed in 1Q? And if you could talk to the gross margin impact as well?

    好的,這很有幫助。然後再追問一個問題。關於你們在國際上進行的經銷商收購,想請你量化一下本季看到的貢獻,以及我們往後應該如何看待?另外,除了你們在第一季執行的那些之外,未來幾季是否還會有其他我們應該預期的收購?也請談談對毛利率的影響?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, I'll take that one, Rich. This is John. The impact is very, very small. We just closed those deals in the first quarter, so there's really not much of a material effect that we saw. But it is in line with our overall strategy where we want to be able to have our own sales team, go to -- work in those markets and try to grow faster. So it continues and it's part of our strategy but there really is, a really small effect to start in the first quarter.

    是的,Rich,這題我來回答。我是John。影響非常、非常小。我們是在第一季才剛完成這些交易,所以我們看到的實質影響並不大。但這符合我們的整體策略:我們希望能擁有自己的銷售團隊,進入——在那些市場運作並嘗試更快成長。所以這會持續進行,也是我們策略的一部分,但第一季一開始的影響確實非常小。

  • Operator

    Operator

  • Our next question comes from line of Steven Valiquette of Bank of America Merrill Lynch.

    下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的Steven Valiquette。

  • Steven J. James Valiquette - Former MD

    Steven J. James Valiquette - Former MD

  • I'll also congratulate you guys. Those are some pretty strong results.

    我也要恭喜各位。這些結果相當強勁。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Steve.

    謝謝,Steve。

  • Steven J. James Valiquette - Former MD

    Steven J. James Valiquette - Former MD

  • So the average selling price number looks pretty solid and probably reflects at least -- the other price increase you took several months ago. But just on pricing in the market, and we did notice that ClearCorrect, you announced the shift in their pricing at AAO over the weekend where now practitioners can pay per aligner. It's probably only have impact maybe on the low-end of the market but just curious if you have any thoughts about their pricing change and whether it really matters for Align overall?

    所以平均售價(ASP)看起來相當穩健,可能至少反映了——你們幾個月前進行的那次價格調整。但就市場定價而言,我們也注意到ClearCorrect,你們在週末的AAO上宣布調整其定價方式,現在醫師可以按每副牙套(aligner)付費。這可能只會對市場低端有影響,但想請教你對他們這次定價變更有何看法,以及這對Align整體而言是否真的重要?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, Steve. I think, I mean, I saw that too. It was pretty well presented by ClearCorrect. I think if you have the kind of product that they have, that's a pretty simple way to go to marketplace. And so we don't see that changing our strategy because when you look at the sophistication of our product line and how it is directed towards certain malocclusions and the number aligners associated with it, our pricing makes sense in that way. But if you're ClearCorrect, you know I'd say that, that was a simple way to go about it. And I think it makes sense in that end of the marketplace.

    是的,Steve。我想,我的意思是,我也看到了。ClearCorrect的呈現相當到位。我認為如果你擁有他們那種產品,這是一種相當簡單的市場切入方式。因此我們不認為這會改變我們的策略,因為當你看我們產品線的成熟度、它如何針對特定咬合不正(malocclusions)以及與之相關的牙套數量時,我們的定價在那樣的架構下是合理的。但如果你是ClearCorrect,你知道我會說,那是一個簡單的做法。而且我認為在那個市場端確實說得通。

  • Operator

    Operator

  • Our next question comes from the line of Jon Block of Stifel.

    下一個問題來自Stifel的Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • I'll limit myself to 2 questions. First one is just international, I mean big, big numbers, diverse growth. EMEA was up 38%, Joe. A big acceleration from the 4Q '16 number of up 20%. And I know 4Q '16 had some sort of EMEA backlog moving parts, if you would. So just maybe your thoughts on how that market is growing? Is the best to look at it, I guess, what I'm asking is somewhere in between that 20% deceleration that we saw exiting '16 and the big 38% number that you put up in 1Q '17?

    我把自己限制在兩個問題。第一個是關於國際市場:數字非常、非常大,成長也很分散多元。Joe,EMEA成長了38%。相較於2016年第四季成長20%,這是很大的加速。我知道2016年第四季在EMEA可能有一些積壓訂單(backlog)等因素在變動。所以想請你談談那個市場的成長狀況?我想問的是,最佳的解讀是否應該介於我們在2016年末看到的20%放緩與你們在2017年第一季交出的38%高成長之間?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • You know, John, that's a great question. They came back very strong and I'd say that, in this case, we continue to do incredibly well in Spain. You see us in the U.K., both from a GP standpoint, orthodontic standpoint continues to grow and we're seeing great strength out of Germany also, France. So by country, when I look at that, and given -- I spent a lot of years over in Europe too, all those countries are so different when you see that kind of acceleration and growth across each one of those countries, you know the team is executing well on the strategy across all the different cultures. I honestly would say, it's hard to explain exactly what happened in the fourth quarter in EMEA. I would tell you that internally, we probably did not guess the vacation schedule as well as what happened in Europe. And we had some bleed over, obviously, from a case shipment standpoint. And I'd say in general, we, as a company, we haven't anticipated well the turndown in the holidays in Europe and how that can affect case growth. So I think behind your question, John, there's -- we're executing well over there, we're excited about it. Obviously, there's this expansion that we've done in the Middle East and Russia with this next distributor acquisition is something we know how to do. We've proven, we really can grow from that. I'm confident we can continue to drive some pretty impressive numbers out of Europe as the team continues to execute there.

    你知道,John,這是個很好的問題。他們回來得非常強勁,我會說,在這個情況下,我們在西班牙持續表現得非常好。你看到我們在英國,無論從全科牙醫(GP)角度或正畸角度都持續成長;我們也看到德國、法國的表現非常強。所以按國家來看,當我看到那樣的情況,而且考量到——我也在歐洲待過很多年——這些國家彼此差異很大;當你看到每個國家都出現那種加速與成長,你就知道團隊在不同文化下都把策略執行得很好。老實說,很難精確解釋第四季在EMEA到底發生了什麼。我會告訴你,內部而言,我們可能沒有把歐洲的休假安排預估得那麼好。而且很明顯地,從病例出貨(case shipment)的角度來看,我們有一些延後到下一季的情況。整體來說,作為一家公司,我們過去對歐洲假期期間的下滑預期不足,以及它如何影響病例成長的評估不夠到位。所以我想在你問題背後,John,重點是——我們在那邊執行得很好,我們也很興奮。顯然,我們在中東與俄羅斯的擴張,加上下一個經銷商收購,是我們熟悉且擅長的事。我們已經證明,我們確實能藉此帶動成長。我有信心,隨著團隊持續在那裡執行,我們能繼續在歐洲推動相當亮眼的數字。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay, very helpful. And then the other one just specific to SDC, it seems that the cases that you guys were providing them are sort of in an infancy stage. But Joe, I'd love your thoughts on how that -- you came with the agreement 9 months ago or so. How that doctor-directed at-home market has progressed and are they cannibalizing a ton of Align cases? I guess, what I'm trying to figure out, is there a component in this where you have another player out there talking about Clear Aligners, spending marketing dollars? Is that helping to sort of stimulate the entire market, which could be a precursor for what happens when some of the other big ortho companies, if they do come out with their Clear Aligner products?

    好的,非常有幫助。第二個問題是更聚焦在SDC:看起來你們提供給他們的病例還處於相對早期的階段。但Joe,我很想聽聽你的看法——你們大約在9個月前達成協議。那個由醫師主導的居家市場(doctor-directed at-home market)發展得如何?他們是否大量侵蝕(cannibalize)Align的病例?我想釐清的是,這裡是否有一個面向:市場上有另一個玩家在談透明牙套(Clear Aligners)、投入行銷費用?這是否正在幫助刺激整體市場,並可能成為某種前兆——當其他大型正畸公司如果真的推出他們的透明牙套產品時,市場可能會發生什麼?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, John -- you know John, I -- we think that this is helping to stimulate the whole Clear Aligners category. SDCs, they are spending a lot of money, they're very good in a sense of how they advertise. We see that as we go to marketplace too. So I do think that's a component in the growth of the marketplace right now. I'd also caution you, John. As the other Clear Aligner companies come in, I don't expect big consumer spends. These are companies that you normally just sell to orthodontists through their channels or through distribution channels. They're not used to massive consumer advertising campaigns and the associated expenses associated with that. So I'm not so sure that the next list of competitors, and you can reel them off as much as I can, are going to come into the marketplace with that kind of gunpowder to go directly-to-consumer. I don't think the SDC and our model will be broadly duplicated with the next round of competition.

    是的,John——你知道 John,我——我們認為這正在幫助刺激整個透明矯正器(Clear Aligners)品類。SDC 他們花了很多錢,他們在某種程度上很擅長做廣告。我們在走向市場時也看到了這一點。所以我確實認為,這是目前市場成長的一個組成因素。我也要提醒你,John。隨著其他透明矯正器公司進入,我不預期會有很大的消費者端支出。這些公司通常只是透過他們的通路或經銷通路賣給矯正醫師。他們不習慣大規模的消費者廣告活動,以及與之相關的費用支出。所以我不太確定下一批競爭者——你能像我一樣把他們一個個列出來——會帶著那種火力進入市場、直接面向消費者(direct-to-consumer)。我不認為 SDC 和我們的模式會在下一輪競爭中被廣泛複製。

  • Operator

    Operator

  • Our next mission comes from the line of Jeff Johnson of Robert W. Baird.

    我們下一個提問來自 Robert W. Baird 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Let me ask maybe 2 revenue questions, and then I have a margin question as well. But Joe, on the revenue, the guidance you're giving for second quarter and then for the full year, it would seem to imply a slowdown in the second half to maybe 20% revenue growth. And given the strength this quarter, it's almost hard to imagine, which just a couple of quarters ago, that would've been a good number. And so just trying to figure out if there's just conservatism in there? What kind of -- how you're thinking about the second half playing out? And then on the international side. For a long time, we've kind of heard the story that you need to continue to invest in the international markets to really kind of sustain 30% growth. You'd tick up to 40% this quarter, is that kind of -- should we be thinking about sustainability now above 30% in the international markets at least in the near-term?

    我想先問大概兩個營收問題,然後我也有一個毛利率問題。不過 Joe,就營收而言,你對第二季以及全年給出的指引,似乎意味著下半年會放緩到大約 20% 的營收成長。考量到本季的強勁表現,這幾乎讓人難以想像——而就在幾季前,那會是一個不錯的數字。所以我只是想釐清,這裡面是否只是比較保守?你們是如何看待下半年可能的走勢?另外在國際市場方面。很長一段時間以來,我們聽到的說法是,你需要持續投資國際市場,才能真正維持 30% 的成長。本季你們跳升到 40%,那麼在國際市場至少在短期內,我們是否應該把可持續性看作是 30% 以上?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Okay, Jeff. This is John. I'll take the question. On revenue, what we've seen in the first half is you saw great performance in the first quarter. We continue to see that as we head into the second quarter. Strong performance and we're guiding to the high side of what we had in our long-term model of case shipments on our high set of 27%. Our strategies are playing out. We're seeing that in what we've seen in volume and that's why we felt comfortable of taking this to the high-end of our guidance to closer to that 25% for the year. And as we get through this quarter and the second quarter, we'll revisit that if that volume continues, to where we see it. So right now it's not being conservative, we're just kind of calling what we see. And then in terms of the growth that you saw -- that you were talking about, was it specifically for international? Or are you -- was it...

    好的,Jeff。我是 John。我來回答這個問題。在營收方面,我們在上半年看到的是:第一季表現非常好。進入第二季時我們也持續看到同樣的趨勢。表現強勁,而我們在出貨病例(case shipments)的長期模型中,指引也給到高端、也就是 27% 的高檔區間。我們的策略正在發揮作用。我們從量的表現中看到了這點,因此我們有信心把全年指引提高到更接近 25% 的高端。當我們走完本季與第二季後,如果這樣的量能持續,我們會再重新檢視,看看我們所看到的情況。所以目前不是保守,而是我們只是如實反映我們所看到的。另外,關於你提到的成長——你說的是特別指國際嗎?還是你——是指……

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • EMEA or APAC or...

    EMEA 或 APAC 或……

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes, and pretty much just rolling international up all together. We've kind of long thought of that as the sustainable 30% or 25% to 30% and you have to keep investing to maintain that kind of number. And now we see it up to 40%. Just wondering how sustainable is that here going forward?

    是的,基本上就是把國際市場整體加總來看。我們長期以來一直認為那是可持續的 30% 或 25% 到 30%,而且你必須持續投資才能維持那樣的數字。現在我們看到它來到 40%。只是想問,往後這樣的水準有多可持續?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, so we definitely still have volume opportunities in these developing countries. So that is growth opportunities for us. We've mentioned on the earlier part of this call about some of the distributor deals and some of the things that we're going direct. That should help us with some of the volume. But we're still seeing a lot of growth and a lot of opportunities in places like China and parts of EMEA and so on. And we're going to continue to push for that growth where we can and we expect it to continue to keep growing like it has.

    是的,所以我們在這些開發中國家確實仍有量的機會。因此那對我們而言是成長機會。我們在本次電話會議前段提到了一些經銷商合作案,以及一些我們改為直營(go direct)的事項。那應該會在量的部分幫助我們。但我們仍在像中國、以及 EMEA 的部分地區等地方看到很多成長與機會。我們會在可行之處持續推動這些成長,也預期它會像目前一樣持續成長。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Fair enough. And then just on the margin side. A couple of quarters, your margins have been down. Your guidance -- for the full year, obviously, flat to up slightly. So many initiatives going on at this point that's really helping support that top line. I guess, what gives you the confidence? And where does the margin improvement come from, I guess, going forward with all this investment that you've got going on at this point?

    了解。那再談毛利率。過去幾季你們的毛利率一直在下滑。你們對全年指引顯然是持平到小幅上升。目前有這麼多計畫在進行,確實在支撐營收成長。我想問,你們的信心來源是什麼?在你們目前進行這些投資的情況下,未來毛利率改善主要會來自哪裡?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I mean what we've seen, Jeff, so far is we've invested as we have, really last year and now into this year up front, with a lot of our sales initiatives and our marketing expenses, up front we're seeing that volume come through and that's happened in the first quarter and expect it to continue into the year. And that's what gives us confidence in holding our margin rate flat to slightly up from last year.

    是的。Jeff,我們目前看到的是:我們已經如同計畫進行投資,主要是在去年以及今年前段,投入了許多銷售推動與行銷費用;而在前期投入之後,我們看到量開始反映出來——第一季已經發生,我們也預期全年會持續。這就是我們有信心把毛利率維持在與去年持平到小幅上升的原因。

  • Operator

    Operator

  • Our next question comes from the line of Robert Willoughby of Crédit Suisse.

    我們下一個問題來自 Crédit Suisse 的 Robert Willoughby。

  • Robert Mcewen Willoughby - Former MD & Senior Research Analyst

    Robert Mcewen Willoughby - Former MD & Senior Research Analyst

  • You mentioned the ERP process is keep -- is driving that DSO number higher. You say it's kind of a several quarter phenomena but can you give us any granularity around that? That's -- it's getting to be a larger number. So when's a reasonable timeframe to see that number turn over and see the cash start to improve?

    你提到 ERP 流程正在——正在推升 DSO 這個數字。你說這算是跨好幾季的現象,但你能否提供一些更細的說明?那——它正變成一個更大的數字。那麼,合理的時間點是什麼時候可以看到這個數字回轉,並看到現金流開始改善?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Robert. It's up to them. We've worked on -- we've worked hard within the company to try to improve. It's not -- the big ERP implementation we had was last July. But we've also been putting on additional entities and going live on our new ERP. And that has caused us to struggle a little bit in terms of getting some of those collections and moving from one system to another, getting customers and our collectors to kind of be in sync. We expect that it's going to start to come down as we go through this year. And some of the initiatives that we have that to be -- we're really focused on those collections and also, work on our ERP to make sure that we're able to fix some of these issues that we have. But we expect it to start coming down.

    是的,Robert。這取決於他們。我們在公司內部一直努力改善——我們非常努力。大型 ERP 導入是在去年 7 月。但我們也持續新增其他法人實體並在新的 ERP 上線。這讓我們在收款方面遇到一些挑戰,因為要從一個系統移轉到另一個系統,並讓客戶與我們的催收人員在流程上同步。我們預期在今年進行的過程中,這個數字會開始下降。我們也有一些措施——我們非常聚焦在收款,同時也會在 ERP 上持續改善,確保能修正目前遇到的一些問題。但我們預期它會開始下降。

  • Robert Mcewen Willoughby - Former MD & Senior Research Analyst

    Robert Mcewen Willoughby - Former MD & Senior Research Analyst

  • Okay, and there's no bad debt experience of consequence?

    好的,那沒有任何顯著的壞帳經驗嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No, what we've seen is as we've tested and has gone through, it's just taking longer for us to collect but it's not turning into bad debt. It's just a slower paying that we normally experience. But the bad debt has not increased.

    沒有,我們看到的是,隨著我們測試並逐步走過流程,只是收款時間變長,但並沒有變成壞帳。只是付款速度比我們通常的經驗更慢。但壞帳並沒有增加。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Thanks, Rob. One last question, please?

    謝謝你,Rob。最後一個問題,可以嗎?

  • Operator

    Operator

  • Our next question comes from the line of Brandon Couillard of Jefferies.

    下一個問題來自 Jefferies 的 Brandon Couillard。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Not to disparage the results at all but I'm curious if the North American GP experience in the first quarter was in line or maybe better than your plan? It seems that it was more in line if I suppose with typical seasonality whereas, we saw the rest of the business really pick up in the first quarter versus historical trend. Just your thoughts there?

    並非要貶低這些成果,但我很好奇北美 GP 在第一季的表現,是符合你們的計畫,還是可能優於你們的計畫?看起來它更像是符合典型的季節性;而我們看到業務其他部分在第一季相較於歷史趨勢明顯回升。想聽聽你們的看法?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Hi, Brandon. It's Joe. I'd say it's in line to trending up. Maybe, slightly stronger than what we thought. I'd say it straight -- it probably came from, like we mentioned, DSOs more than anything and our work with them. So we felt good about the quarter in that sense. And not dramatic but I'd say, it's turning up.

    嗨,Brandon。我是 Joe。我會說大致符合、並且呈現上升趨勢。可能比我們原先想的稍微強一些。我直說——這大概主要來自我們先前提到的 DSO,以及我們與他們的合作。所以從這個角度來看,我們對這一季的表現感到滿意。雖然不算戲劇性,但我會說確實在往上走。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Okay then, one more. I'm curious if you have any data or you even track this, in terms of like the new iTero shipments last year was a big year in terms of how many of those go to non-Invisalign docs? And kind of what the uptake trajectory or trend might be from doc to get one of the new scanners through the -- translating those into pull through for new case starts?

    好的,那再一個。我好奇你們是否有任何數據,或你們是否有追蹤:去年新的 iTero 出貨量很大,其中有多少是賣給非 Invisalign 醫師?以及從醫師取得新掃描器之後的採用軌跡或趨勢——也就是把這些轉化為新病例啟動(case starts)的拉動效應(pull-through)?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • That's always kind of a magic question around the table here. It's -- we do know that we do see an uptick in uses of Invisalign when we sell Invisalign to an account. Usually, that account has already been associated with Invisalign in some way, Brandon. But we haven't been able to quantify that. Sometimes, it's a blip, sometimes it's bigger. It -- sometimes it tends to kind of fall back down to the initial line as an Invisalign customer at some point. But we certainly know that once a customer does get an Invisalign scanner, they tend to do more Invisalign cases. And frankly, we can bring more power to that customer in the sense of the software and the ease of the use of the product line that we really start to build in with the iTero scanner. As far as how many we sell to non-Invisalign accounts, I really don't have that data and I don't think we have kept track of that data at all.

    這一直是我們這邊桌上常見的「魔術問題」。我們確實知道,當我們把 Invisalign 賣給某個客戶時,會看到 Invisalign 使用量的提升。通常那個客戶在某種程度上本來就與 Invisalign 有所關聯,Brandon。但我們一直無法把它量化。有時候只是短暫跳升(blip),有時候幅度更大。有時候在某個時間點,它又會回落到一開始作為 Invisalign 客戶的基準線。但我們確實知道,一旦客戶擁有 Invisalign 掃描器,他們通常會做更多 Invisalign 病例。坦白說,我們也能在軟體與產品線易用性上為客戶帶來更強的能力,而這些正是我們透過 iTero 掃描器逐步建立起來的。至於我們賣給非 Invisalign 客戶的數量,我手上真的沒有那個數據,而且我也不認為我們有追蹤那個數據。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Operator, we'll take one more question, please?

    接線員,我們再接一個問題,麻煩?

  • Operator

    Operator

  • Our last question will come from the line of John Kreger of William Blair.

    最後一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Joe, given the nice uptick in growth, what is your sense about the underlying market on the ortho side? Are your customers reporting any changes in their sort of typical case start growth? Or is this all share gains on your part?

    Joe,鑑於成長出現不錯的上升,你對矯正(ortho)端的基本市場狀況有何看法?你們的客戶是否回報他們典型的新病例啟動成長有任何變化?還是這全部都是你們的市佔提升?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, I mean, we're seeing an increase of orthodontic patients through the orthodontists that we track and we talk to. So we do have a healthy orthodontic market behind us, there's no doubt. I think our teen expansion shows that we have taken significant share in that area too. So look, it's wonderful to have a good -- a stronger market behind you like that, but this is a story of a strong market and a share shift at the same time.

    嗯,我的意思是,我們透過我們追蹤並交流的矯正醫師,看到矯正患者人數在增加。所以我們背後確實有一個健康的矯正市場,這點毫無疑問。我認為我們在青少年市場的擴張也顯示,我們在那個領域同樣取得了顯著的市佔。所以你看,背後有這樣更強的市場當然很好,但這同時是一個強勁市場與市佔轉移並存的故事。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • And what do you view as the underlying market growth? We'd sort of put it maybe at about 4% on a unit basis. Would that be in sync with what you hear from your customers?

    那你認為基本市場的成長率是多少?我們大概會把它估在單位數量(unit)基礎約 4%。這會和你從客戶那邊聽到的相一致嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, right on.

    是的,完全一致。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Okay, great. And then one other one. The very good growth in DSOs, I assume that's primarily in North America. Can you just talk a little bit about what your strategy has been to drive that? Or has it really been just as those entities get bigger, they viewed Invisalign as a good same-store growth driver? Just curious what you're seeing?

    好的,很好。然後還有一個。DSO 的成長非常好,我猜主要是在北美。你能否談談你們推動這件事的策略是什麼?或者其實只是因為那些機構變大之後,把 Invisalign 視為一個很好的同店成長驅動因素?只是好奇你們看到的是什麼?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Look, it kind of -- John, you've led the question really well, I mean it's kind of a story at a DSO level. As soon as you join the DSO, it's all about growth, right? And we're trying to transfer best practices on growth and efficiency across all the different units that they have. Invisalign's a great story because you can attract more patients with Invisalign, you have a different revenue source and you tend those patients to attract with Invisalign. You tend to keep them over time, too. And so you know, we incentivize these customers, we train them as much as we possibly can. We work to make it as easy to use Invisalign, as possible. And it's worked out well. Obviously, Heartland's been a good partner for us and so were other DSOs that we have out there. And it's a good business partnership in that sense but from all the work we have to do to work together to get the right advertising in place, demographics from a patient identification standpoint, the training is necessary for each one of those. But DSOs can really help to facilitate that based on the kind of organization that they are.

    你看,John,你這個問題鋪陳得很好——這其實有點像是 DSO 層級的故事。一旦加入 DSO,重點就是成長,對吧?而我們正嘗試把成長與效率的最佳實務,移轉到他們旗下所有不同的據點。Invisalign 是個很好的故事,因為你可以用 Invisalign 吸引更多患者,帶來不同的營收來源,而且你用 Invisalign 吸引來的患者,往往也會長期留存。因此,我們會激勵這些客戶,並盡可能多地訓練他們。我們也努力讓 Invisalign 盡可能容易使用。而這些做法的效果很好。顯然,Heartland 一直是我們很好的合作夥伴,我們其他的 DSO 夥伴也是如此。從這個角度來看,這是一個良好的商業合作關係;但我們也必須一起做很多工作,包含把適當的廣告到位、從患者識別的角度看的人口統計(demographics),以及每一家據點都需要的訓練。不過,DSO 基於其組織型態,確實能大幅協助促成這些事情。

  • Operator

    Operator

  • There are no further questions over the audio portion of the conference. I would like to turn the conference back over to management for closing remarks.

    音訊部分已無其他提問。我想把會議交回管理層作結語。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Well thank you, everyone, for joining us today. This concludes our conference call. If you have any follow up questions, please contact Investor Relations. Have a great day.

    好的,感謝各位今天加入我們。本次電話會議到此結束。如有任何後續問題,請聯絡投資人關係部門。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time. Have a wonderful rest of your day.

    今天的會議到此結束。感謝各位的參與。您現在可以掛斷電話線。祝各位今天剩餘時間愉快。